Every 8-K that Global Medical REIT Inc. (GMRE) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow GMRE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GMRE filings page.
Chiron Real Estate Inc. expanded its senior housing portfolio by closing two acquisitions in Alexandria, Virginia. It bought The Landing Alexandria for $130 million and The Riviera Alexandria for $118.9 million, and will operate both as senior housing operating property assets under third‑party management by Greystone Communities.
To support these deals, the company completed a private placement of 1,000,000 shares of 6.00% Series C Convertible Preferred Stock at $100.00 per share for gross proceeds of about $100,000,000, and incurred approximately $147 million of additional borrowings under its Third Amended and Restated Credit Facility. It designated 1,000,000 shares as Series C Convertible Preferred Stock and created economically similar Series C Convertible Preferred Units at the operating partnership level, with new distribution restrictions applying if preferred distributions are not declared.
Chiron Real Estate Inc. reported several governance and capital actions from its 2026 annual meeting. The Board expanded from six to seven members and appointed Charles Fitzgerald as a director, with service through the 2027 annual meeting and committee roles on Compensation and Nominating and Corporate Governance.
Stockholders approved an amendment to the 2016 Equity Incentive Plan, extending its term to May 20, 2036 and increasing shares reserved for issuance by 300,000. They also approved, on an advisory basis, executive compensation and ratified Deloitte & Touche LLP as independent auditor for 2026.
In a related press release, Chiron highlighted that Mr. Fitzgerald holds 97,293 shares of its common stock via affiliated entities, and announced second quarter 2026 preferred dividends: $0.46875 per share on Series A and $0.50 per share on Series B, both payable July 31, 2026 to holders of record on July 15, 2026.
Chiron Real Estate Inc. entered into an investment agreement with Maewyn XRN LP and other purchasers for a private placement of up to $100.0 million of new 6.00% Series C Convertible Perpetual Preferred Stock.
The company may sell up to 1,000,000 Series C shares at $100.00 per share in tranches, with an initial funding of at least $25.0 million expected to close on or before June 20, 2026. The preferred stock carries a 6.00% cash dividend that can step up over time, ranks senior to common stock, and is convertible into common stock at an initial implied price of $43.00 per share, subject to anti-dilution and 19.9% ownership caps before stockholder approval.
Chiron will pay a 3% commitment fee on the $100.0 million commitment and reimburse up to $250,000 of investor legal fees, and expects to use proceeds for general business, working capital and potential acquisitions. Maewyn receives board nomination, consent and standstill rights, while holders gain registration rights and warrants in certain redemption scenarios.
Chiron Real Estate Inc. is reshaping itself into a growth-focused healthcare REIT, pairing large senior housing investments with new strategic capital and a lower dividend. The company agreed to acquire three luxury seniors housing communities from Silverstone for an aggregate $425 million, to be operated as seniors housing operating properties (SHOP) and managed by Greystone. It also entered into a $100 million delayed-draw 6.00% Series C convertible preferred equity facility with Maewyn Capital Partners, with an initial conversion price of $43.00 per common share.
To retain more cash for growth, the Board reset the monthly common dividend to $0.16 per share for July–September 2026, a quarterly total of $0.48 versus $0.75 for April–June, an approximate 36% reduction. For the quarter ended March 31, 2026, rental revenue was $38.0 million, net income was $1.7 million and net loss attributable to common stockholders was $0.7 million, or $(0.06) per share. Core FFO was $16.0 million, or $1.11 per share and unit, flat year over year, while same-property cash NOI rose 3.2% and leased occupancy was 95.4%. Net consolidated debt was about $664.9 million and the company reported no debt maturities in 2026 or 2027, with $220.5 million of credit facility borrowing capacity as of May 5, 2026.
Chiron Real Estate Inc. entered into a Master Note and Guaranty Agreement with NYL Investors LLC and certain affiliates, creating an uncommitted senior note facility for its operating partnership. The facility permits issuance of senior unsecured notes in one or more series with an aggregate outstanding principal of up to $150.0 million.
Notes may be issued for up to three years from the agreement’s effective date, subject to earlier termination events, and each series will mature within ten years of issuance. Each issuance must be at least $10.0 million, with interest set at issuance as a spread over U.S. Treasuries and paid quarterly or semi-annually. The operating partnership may prepay the notes, subject to a customary make-whole amount, and the notes rank equally with its other senior unsecured debt.
Chiron Real Estate Inc., formerly Global Medical REIT, reported 2025 results, updated its capital strategy and completed a corporate rebrand. For 2025, total revenue was $148.2 million and the company recorded a net loss of $6.9 million, driven in part by $13.0 million of property impairments.
FFO attributable to common stockholders and noncontrolling interest was $57.6 million ($3.97 per share and unit), while Core FFO reached $65.8 million ($4.53 per share and unit). Leverage was 44.4% at December 31, 2025, with $653.9 million of consolidated debt at a 3.74% weighted average interest rate and no maturities in 2026 or 2027.
The board kept the annualized common dividend at $3.00 per share but shifted to monthly payments, declaring $0.25 per share for each of April, May and June 2026. The company invested $7.1 million for a 49% interest in an active adult joint venture and set 2026 Core FFO guidance at $4.30 to $4.45 per share and unit. A key tenant, White Rock Medical Center, filed for Chapter 11, and Chiron carried a $1.4 million net receivable from its support efforts.
Global Medical REIT Inc. reported that director Henry Cole has informed the Board that he intends to step down as a director, effective at the Company’s 2026 Annual Meeting of Stockholders. He will not be nominated for re-election, and his service will end when his current term expires on the date of that meeting.
The Company states that Mr. Cole’s decision to step down is not due to any disagreement with Global Medical REIT Inc. on matters related to its operations, policies, or practices, indicating an orderly and planned board transition rather than a dispute-driven change.
Global Medical REIT Inc. reported that director Ronald Marston has informed the Board that he intends to retire as a director, effective at the company’s 2026 Annual Meeting of Stockholders. He will not stand for re-election, and his service will conclude when his current term expires at that meeting. The company stated that Mr. Marston’s decision to retire is not due to any disagreement with Global Medical REIT regarding its operations, policies, or practices, indicating this is a planned governance transition rather than a response to a specific dispute.
Global Medical REIT Inc. is issuing a new series of preferred stock to raise capital through an underwritten public offering. The company agreed to sell 2,000,000 shares of its 8.00% Series B Cumulative Redeemable Preferred Stock at a public offering price of $25.00 per share, with a 30-day option for underwriters to purchase up to an additional 300,000 shares at the same price to cover over-allotments. The offering is expected to close on November 20, 2025, subject to customary conditions.
In connection with this, the operating partnership amended its agreement to allow issuance of up to 2,300,000 Series B Preferred Units with a $25.00 per unit liquidation preference, designed to mirror the economic terms of the preferred stock. The company intends to contribute the net proceeds from the Series B Preferred Stock to the operating partnership in exchange for an equal number of these units. Articles Supplementary designate 2,300,000 preferred shares as Series B, and if distributions on the Series B are not declared for any period, the company’s ability to pay distributions or make redemptions on junior or parity stock will be subject to specified restrictions.
Global Medical REIT Inc. (GMRE) reported a third‑quarter 2025 net loss attributable to common stockholders of approximately $6.0 million, or $0.45 per diluted share, compared with net income of approximately $1.8 million, or $0.14 per diluted share, in the prior‑year period. For the nine months ended September 30, 2025, net loss attributable to common stockholders was approximately $4.7 million, or $0.35 per diluted share, versus a net loss of approximately $0.6 million, or $0.04 per diluted share, a year earlier.
Operating metrics were mixed. Same‑store cash NOI grew 2.7% year over year in Q3. Adjusted EBITDAre was $25.7 million for the quarter, with Net Debt/Annualized Adjusted EBITDAre at 6.9x. The portfolio was 95.2% occupied as of September 30, 2025, spanning approximately 5.2 million leasable square feet and generating $118.4 million annualized base rent. Weighted average lease term was 5.3 years. The rent mix was about 72% outpatient medical buildings, 25% inpatient rehabilitation facilities, hospitals, and LTACHs, and 3% other medical real estate.
Global Medical REIT Inc. (GMRE) furnished its Third Quarter 2025 results materials. On November 4, 2025, the company announced its financial position as of September 30, 2025 and operating results for the three and nine months ended September 30, 2025. The earnings release (Exhibit 99.1) and earnings supplemental (Exhibit 99.2) were posted to its website and furnished with this report.
The materials are furnished, not filed, under the Exchange Act and are not subject to Section 18 liabilities, nor incorporated by reference into other filings.
Global Medical REIT Inc. amended its credit facilities to extend maturities and reprice a spread adjustment. The $400M revolver maturity is extended to October 2029 with two six-month extension options exercisable by the company to push the maturity to October 2030. The existing $350M term loan is split into three tranches: a $100M term loan maturing October 2029, a $100M term loan maturing October 2030, and a $150M term loan maturing April 2031. The amendment also removes a prior 0.10% (10 basis point) SOFR credit spread adjustment on all facility borrowings.
Global Medical REIT Inc. approved and implemented a one-for-five reverse stock split of its common stock. Effective as of 5:00 p.m. Eastern Time on September 19, 2025, every five shares of issued and outstanding common stock were converted into one share.
The reverse split temporarily changed the par value of common stock from $0.001 to $0.005 per share at the effective time, then immediately reverted it back to $0.001 per share. Authorized common shares were proportionately reduced from 500,000,000 to 100,000,000, while the 10,000,000 authorized preferred shares and their par value were unchanged.
The common stock will begin trading on a reverse split-adjusted basis on the NYSE on September 22, 2025, continuing under the symbol GMRE with a new CUSIP. Fractional share interests will be paid in cash based on the September 19, 2025 NYSE closing price, and all record holders are affected uniformly aside from minor changes from eliminating fractions. Equity plan share limits, outstanding awards, and related price-based performance metrics were adjusted proportionately.
Global Medical REIT Inc. (NYSE: GMRE) filed an 8-K disclosing a CEO transition effective 23 Jun 2025. Jeffrey M. Busch has been removed as Chief Executive Officer and President and will remain non-executive Chairman. The Board simultaneously appointed Mark O. Decker, Jr. (age 49) as CEO, President and Board member, expanding the Board from seven to eight seats.
The filing provides a detailed three-year employment agreement between Inter-American Management LLC and Mr. Decker:
- Base salary: $700,000 per year.
- Target annual cash bonus: ≥100 % of base salary, prorated for 2025 (60 % cash / 40 % LTIP Units).
- Equity incentives: one-time $1 million LTIP award on the Effective Date; $1.2 million target LTIP award for 2026.
- Relocation stipend: $75,000.
Severance for a "Qualifying Termination" equals 2× (base salary + greater of target or prior-year bonus), pro-rated bonus, accelerated vesting of equity, and up to 18 months of subsidized health coverage. Enhanced benefits (up to 3× multiplier) apply upon qualifying terminations linked to a change in control. Definitions of "good reason" and "cause" are standard for REIT executives.
Mr. Decker’s prior roles include Managing Partner at Proterra Value Investors (2023-2025) and CEO/CIO of Centerspace (NYSE: CSR, 2017-2023). The filing states no family relationships or related-party transactions.